Research programme: chronic lymphocytic leukaemia biomarkers - KineMed
Latest Information Update: 22 Dec 2014
At a glance
- Originator KineMed
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Chronic lymphocytic leukaemia
Most Recent Events
- 18 Nov 2014 Early research in Chronic lymphocytic leukaemia (Diagnosis) in USA (unspecified route)